Last Updated: November 16, 2026

Investigational Drug Information for Seltorexant

« Back to Dashboard


What is the drug development status for Seltorexant?

Seltorexant is an investigational drug.

There have been 19 clinical trials for Seltorexant. The most recent clinical trial was a Phase 2 trial, which was initiated on July 25th 2024.

The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Janssen Research & Development, LLC, Minerva Neurosciences, and [disabled in preview].

There are three US patents protecting this investigational drug and fifty-nine international patents.

Recent Clinical Trials for Seltorexant
TitleSponsorPhase
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsJanssen Research & Development, LLCPHASE3
A Study of Seltorexant in Participants With Probable Alzheimer's DiseaseJanssen Research & Development, LLCPhase 2
A Study of JNJ-42847922 (Seltorexant) in Healthy ParticipantsJanssen Research & Development, LLCPhase 1

See all Seltorexant clinical trials

Clinical Trial Summary for Seltorexant

Top disease conditions for Seltorexant
Top clinical trial sponsors for Seltorexant

See all Seltorexant clinical trials

US Patents for Seltorexant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Seltorexant ⤷  Start Trial Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators Janssen Pharmaceutica NV , Janssen Research and Development LLC ⤷  Start Trial
Seltorexant ⤷  Start Trial Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Janssen Pharmaceutica (BE) ⤷  Start Trial
Seltorexant ⤷  Start Trial Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Janssen Pharmaceutica NV (BE) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Seltorexant

Drugname Country Document Number Estimated Expiration Related US Patent
Seltorexant Argentina AR078731 2029-10-23 ⤷  Start Trial
Seltorexant Argentina AR114667 2029-10-23 ⤷  Start Trial
Seltorexant Australia AU2010310595 2029-10-23 ⤷  Start Trial
Seltorexant Australia AU2015242975 2029-10-23 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.